patients

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutics being developed…

Read more

GeneOnlineEducational Programs Improve Diabetes Management for Elderly Patients Through Lifestyle ChangesA recent study highlights the role of educational programs in improving diabetes management among elderly populations..1 hour ago

GeneOnlineEducational Programs Improve Diabetes Management for Elderly Patients Through Lifestyle ChangesA recent study highlights the role of educational programs in improving diabetes management among elderly populations..1 hour ago

Read more